Clinical protocol. Tumor site specific phase I evaluation of safety and efficacy of hepatic arterial infusion of a matrix-targeted retroviral vector bearing a dominant negative cyclin G1 construct as intervention for colorectal carcinoma metastatic to liver.
Lenz
Heinz-Josef
HJ
USC Gene Therapy Laboratories, Los Angeles, CA 90089-9025, USA.
Anderson
W French
WF
Hall
Frederick L
FL
Gordon
Erlinda M
EM
D000818:Animals; D002985:Clinical Protocols; D015179:Colorectal Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D056746:Cyclin G; D056766:Cyclin G1; D016213:Cyclins / Q000235:genetics*; D005822:Genetic Vectors / Q000008:administration & dosage / Q000493:pharmacokinetics; D006499:Hepatic Artery / Q000473:pathology; D006801:Humans; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000235:genetics / Q000556:secondary* / Q000628:therapy*; D008297:Male; D051379:Mice; D008819:Mice, Nude; D009374:Neoplasms, Experimental / Q000235:genetics / Q000628:therapy; D012190:Retroviridae
C534702:CCNG1 protein, human; C534703:Ccng1 protein, mouse; D056746:Cyclin G; D056766:Cyclin G1; D016213:Cyclins